Guizhou Bailing Group Pharmaceutical Co., Ltd. (SHE:002424)

SHE:002424 Revenue

Guizhou Bailing Group Pharmaceutical had revenue of 441.04M CNY in the quarter ending September 30, 2026, a decrease of -31.04%. This brings the company's total for the last twelve months to 2.36B, down -25.16% year-over-year. In the year 2025, Guizhou Bailing Group Pharmaceutical had annual revenue of 3.05B, down -20.31%. That makes Guizhou Bailing Group Pharmaceutical the 13,416th largest company in the world by revenue and 2,375th in China.

• Revenue (ttm): 2.36B
• Revenue Growth: -25.16%
• P/S Ratio: 2.46
• Revenue / Employee: 412.70K
• Employees: 5,715
• Market Cap: 5.79B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Industrial 2.49B 67.1%
• Commercial Business 1.13B 30.5%
• Medical Institutions 67.86M 1.8%
• Others 22.80M 0.6%

Fiscal year ended Dec 31, 2025 See the full SHE:002424 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	3.05B	-776.76M	-20.31%
Dec 31, 2024	3.83B	-437.59M	-10.26%
Dec 31, 2023	4.26B	722.84M	20.42%
Jan 1, 2023	3.54B	429.01M	13.79%
Jan 1, 2022	3.11B	23.24M	0.75%

Data Source: S&P Global Market Intelligence Last updated: Oct 23, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 10, 2026

Data Sources Report a data error